{
    "id": 1797,
    "fullName": "BCL2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "BCL2 over exp indicates an over expression of the Bcl2 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 596,
        "geneSymbol": "BCL2",
        "terms": [
            "BCL2",
            "Bcl-2",
            "PPP1R50"
        ]
    },
    "variant": "over exp",
    "createDate": "09/18/2014",
    "updateDate": "05/15/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5229,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human lymphocytes over expressing Bcl2 demonstrated reduced sensitivity to Taxol (paclitaxel) induced apoptosis in culture (PMID: 10432288).",
            "molecularProfile": {
                "id": 1785,
                "profileName": "BCL2 over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4932,
                    "pubMedId": 10432288,
                    "title": "Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10432288"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5225,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCL2 over expression was associated with Taxol (paclitaxel) resistance in a panel of tumor cell lines through multiple factor analysis, and was predictive of Taxol (paclitaxel)-resistance in patient samples (PMID: 26372358).",
            "molecularProfile": {
                "id": 1785,
                "profileName": "BCL2 over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4931,
                    "pubMedId": 26372358,
                    "title": "Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3377,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ABT-737 and Zolinza (vorinostat) synergized to decrease viability of Zolinza (vorinostat)-resistant Bcl2-over-expressing human head and neck squamous cell carcinoma cell lines in culture and to reduce tumor volume in xenografts (PMID: 23274910).",
            "molecularProfile": {
                "id": 1785,
                "profileName": "BCL2 over exp"
            },
            "therapy": {
                "id": 3132,
                "therapyName": "ABT-737 + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 570,
                    "pubMedId": 23274910,
                    "title": "Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23274910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12593,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Venclexta (venetoclax) treatment resulted in an overall response rate of 21% (14/66) in patients with relapsed or refractory multiple myeloma, with 86% (12/14) of responses observed in patients harboring t(11; 14), which lead to higher Bcl2 expression level compared to Bcl2l1 and Mcl1 (PMID: 29018077; NCT01794520).",
            "molecularProfile": {
                "id": 1785,
                "profileName": "BCL2 over exp"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10464,
                    "pubMedId": 29018077,
                    "title": "Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29018077"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transgenic lymphoma mouse model, over expressing MYC and BCL2, treated with JQ1 resulted in a decreased response as indicated by reduced survival (PMID: 27406984).",
            "molecularProfile": {
                "id": 26192,
                "profileName": "BCL2 over exp MYC over exp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6567,
                    "pubMedId": 27406984,
                    "title": "BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406984"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8196,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transgenic murine MYC over expressing lymphoma cells harboring NRAS Q61K demonstrated over expression of BCL2, which resulted in resistance to treatment with JQ1 in culture (PMID: 27406984).",
            "molecularProfile": {
                "id": 26193,
                "profileName": "BCL2 over exp MYC over exp NRAS Q61K"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6567,
                    "pubMedId": 27406984,
                    "title": "BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27406984"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19076,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and VU661013 combination therapy induced apoptosis and reduced tumor burden in a patient-derived xenograft (PDX) model of MCL1-positive and BCL2-dependent disseminated acute myeloid leukemia, however, did not exhibit synergistic effects compared to Venclexta (venetoclax) treatment (PMID: 30185627).",
            "molecularProfile": {
                "id": 33893,
                "profileName": "BCL2 over exp MCL1 pos"
            },
            "therapy": {
                "id": 8905,
                "therapyName": "Venetoclax + VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16724,
                    "pubMedId": 30185627,
                    "title": "A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20780,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, chronic lymphocytic leukemia cells harboring XPO1 E571K with BCL2 overexpression were sensitive to Xpovio (selinexor) treatment in culture and when engrafted into secondary recipients in mouse models (PMID: 31285298).",
            "molecularProfile": {
                "id": 35333,
                "profileName": "BCL2 over exp XPO1 E571K"
            },
            "therapy": {
                "id": 1749,
                "therapyName": "Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17771,
                    "pubMedId": 31285298,
                    "title": "Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1785,
            "profileName": "BCL2 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 16599,
                    "name": "BCL2 inhibitor",
                    "profileName": "BCL2 over exp"
                },
                {
                    "id": 132,
                    "name": "BCL2 Family Inhibitor",
                    "profileName": "BCL2 over exp"
                }
            ]
        },
        {
            "id": 26192,
            "profileName": "BCL2 over exp MYC over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26193,
            "profileName": "BCL2 over exp MYC over exp NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33893,
            "profileName": "BCL2 over exp MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35333,
            "profileName": "BCL2 over exp XPO1 E571K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}